Bruker Corporation $BRKR Stock Holdings Decreased by Curated Wealth Partners LLC

Key Points

• Curated Wealth Partners cut its Bruker stake by 99.1% in the third quarter, selling 495,555 shares and retaining 4,445 shares valued at approximately $288,000. Institutional investors collectively own 79.52% of the company.
• Bruker’s latest quarterly results exceeded expectations, with adjusted EPS of $0.49 versus the $0.38 consensus estimate, while revenue rose 5.2% year over year to $838.5 million but fell short of forecasts.
• Analyst sentiment remains moderately bullish, with a consensus price target of $59.43 and a “Moderate Buy” rating. Bruker also declared a quarterly dividend of $0.05 per share, equating to a 0.4% annual yield.

Curated Wealth Partners LLC lowered its stake in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) by 99.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,445 shares of the medical research company's stock after selling 495,555 shares during the quarter. Curated Wealth Partners LLC's holdings in Bruker were worth $288,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in the stock. Essential Partners LLC purchased a new stake in shares of Bruker during the first quarter valued at about $36,000. Global Retirement Partners LLC purchased a new position in shares of Bruker in the 2nd quarter worth approximately $38,000. EverSource Wealth Advisors LLC raised its stake in shares of Bruker by 532.9% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,500 shares of the medical research company's stock worth $54,000 after acquiring an additional 1,263 shares in the last quarter. FNY Investment Advisers LLC bought a new position in shares of Bruker during the 2nd quarter worth approximately $60,000. Finally, IFP Advisors Inc raised its stake in shares of Bruker by 88.6% during the 2nd quarter. IFP Advisors Inc now owns 1,060 shares of the medical research company's stock worth $64,000 after acquiring an additional 498 shares in the last quarter. Institutional investors own 79.52% of the company's stock.

Insider Activity

In related news, VP Mark Munch sold 2,000 shares of the company's stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $52.87, for a total value of $105,740.00. Following the transaction, the vice president directly owned 134,806 shares of the company's stock, valued at $7,127,193.22. This represents a 1.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 27.20% of the stock is currently owned by insiders.

Bruker Stock Down 3.1%

NASDAQ:BRKR opened at $54.80 on Friday. The company has a market cap of $8.35 billion, a PE ratio of -78.29, a P/E/G ratio of 1.68 and a beta of 1.22. Bruker Corporation has a twelve month low of $32.37 and a twelve month high of $66.98. The company has a current ratio of 1.85, a quick ratio of 0.92 and a debt-to-equity ratio of 0.76. The company's 50 day moving average is $58.79 and its two-hundred day moving average is $53.35.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.38 by $0.11. The business had revenue of $838.50 million for the quarter, compared to analyst estimates of $853.57 million. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. Bruker's revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Analysts anticipate that Bruker Corporation will post 2.12 EPS for the current year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st were issued a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, September 21st. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.4%. Bruker's payout ratio is -28.57%.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on BRKR. TD Cowen increased their target price on shares of Bruker from $60.00 to $62.00 and gave the company a "hold" rating in a research report on Tuesday. Zacks Research lowered shares of Bruker from a "strong-buy" rating to a "hold" rating in a report on Wednesday, September 2nd. Barclays lifted their price target on shares of Bruker from $58.00 to $70.00 and gave the stock an "overweight" rating in a report on Wednesday, October 7th. Guggenheim upped their price target on Bruker from $70.00 to $72.00 and gave the stock a "buy" rating in a research report on Thursday, October 1st. Finally, JPMorgan Chase & Co. reiterated a "neutral" rating and set a $60.00 price objective on shares of Bruker in a report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $59.43.

Bruker Profile

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, chemicals, biological samples and industrial products. Its customers include academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, environmental laboratories and industrial manufacturers.

The company's portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray instruments, microscopy and surface-analysis platforms, molecular spectroscopy systems, and analytical tools for proteomics, spatial biology, metabolomics and materials research.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.